Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes medicines. Oral obesity medication could offer an alternative to injectable medications,

The usual dose of Novo Nordisk’s expensive weight-loss drug Wegovy can be cut in half without affecting the results, researchers reported on Tuesday at the European Congress on Obesity in Malaga, Spain.

New research has shown that Ozempic can cause taste changes in people taking it, even going so far as to make some hate the taste of meat.

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 drug resolved liver inflammation in nearly two-thirds of participants, twice the rate seen with placebo.

One weight loss injection has been branded more effective than another, after scientists carry out the first ever head-to-head trial of Mounjaro and Wegovy.

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies. Compare side effects here.

The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food cravings and is also available for people with a high BMI.